G. Otto

TL;DR: Measurements of TMB from comprehensive genomic profiling are strongly reflective of measurements from whole exome sequencing and model that below 0.5 Mb the variance in measurement increases significantly, demonstrating that many disease types have a substantial portion of patients with high TMB who might benefit from immunotherapy.

TL;DR: Given the limited treatment options and poor prognosis of patients with SCLC, comprehensive genomic profiling has the potential to identify new treatment paradigms and meet an unmet clinical need for this disease.

TL;DR: This research presents a novel and scalable approach to Oncology Biomarker Development that addresses the challenge of integrating cell reprograming and “ ‘spatially aggregating’ signals” into the immune system through a probabilistic approach.

TL;DR: Next-generation sequencing can discover targets of therapy for relapsed and metastatic ACC and shows promise to improve outcomes for this aggressive form of cancer.

TL;DR: The utility of developing PDX banks for modeling human leukemia is demonstrated, and the importance of genomic profiling of PDX and patient samples to ensure concordance is emphasized before performing mechanistic or therapeutic studies.